Vertex Ventures HC invests in various sectors of the healthcare industry, including biopharmaceuticals, medical devices and digital health.
Business Model:
Revenue: $0
Employees: 0-0
Address: 76 South Park Street
City: San Francisco
State: CA
Zip: 94107
Country: US
Vertex Ventures HC invests in various sectors of the healthcare industry, including biopharmaceuticals, medical devices and digital health. Their portfolio includes companies at all stages of development, from early-stage companies testing transformative technologies to commercial-stage companies seeking additional growth. With a focus on areas with significant unmet need, Vertex seeks to build great companies that improve the health and quality of human life. They take an active role in our portfolio companies and work with exceptional entrepreneurs, industry partners and fellow venture investors to create value. Their global investment professionals bring deep scientific, medical and business knowledge to every investment they make.
Contact Phone:
+16507298810
Contact Email:
Announced Date | Company | Transaction | Money Raised |
---|---|---|---|
9/2015 | Kona Medical | Debt Financing | 10M |
7/2013 | SENSIMED | Series C | 8.4M |
3/2017 | Moximed | Series C | 50M |
7/2020 | Elevation Oncology | Series A | 32.5M |
9/2018 | Twentyeight-Seven Therapeutics | Series A | 65M |
9/2014 | Ivantis | Series B | 25M |
10/2017 | Visterra | Series C | 0 |
12/2022 | SonoThera | Series A | 0 |
2/2019 | Nuvaira | Equity | 79M |
10/2022 | Matchpoint Therapeutics | Series A | 70M |
11/2020 | Elevation Oncology | Series B | 65M |
6/2017 | Earlens | Series C | 0 |
10/2018 | Earlens | Series D | 0 |
7/2016 | Innoventure | Series A | - |
12/2019 | Epirium Bio | Series A | 0 |
9/2020 | Palleon Pharmaceuticals | Series B | 100M |
7/2021 | NeuSpera Medical | Series C | 65M |
6/2017 | Bicycle Therapeutics | Series B | 52M |
9/2021 | Allay Therapeutics | Series C | 60M |
10/2014 | Visterra | Series B | 30M |
10/2017 | Palleon Pharmaceuticals | Series A | 47.6M |
6/2016 | Visterra | Series C | 23.1M |
5/2019 | Twentyeight-Seven Therapeutics | Series A | 15M |
4/2015 | Twelve | Series C | 35M |
9/2021 | Obsidian Therapeutics | Series B | 0 |
8/2021 | Sonoma BioTherapeutics | Series B | 0 |
6/2016 | Earlens | Series C | 0 |
6/2019 | BlackThorn Therapeutics | Series B | 76M |
12/2017 | Obsidian Therapeutics | Series A | 0 |
4/2014 | Nuvaira | Series D | 42M |
5/2015 | Moximed | Series B | 33M |
4/2021 | Boundless Bio | Series B | 105M |
5/2023 | Boundless Bio | Series C | 0 |
9/2021 | Allay Therapeutics | Series C | 0 |
9/2021 | Obsidian Therapeutics | Series B | 0 |
8/2021 | Sonoma BioTherapeutics | Series B | 0 |
7/2021 | NeuSpera Medical | Series C | 0 |
4/2021 | Boundless Bio | Series B | 0 |
11/2020 | Elevation Oncology | Series B | 0 |
9/2020 | Palleon Pharmaceuticals | Series B | 0 |
7/2020 | Elevation Oncology | Series A | 0 |
12/2019 | Epirium Bio | Series A | 0 |
6/2019 | BlackThorn Therapeutics | Series B | 0 |
Name | Price |
---|
Name | Size | Announced Date |
---|